Member Info for Toukankahmoon

Good to see that the BB police are out deleting posts they don’t like again

Icecool

This wasn’t an argument until you goaded Wyndrum with your incessant jibes

Deserttrader

Some are in denial but the focus has moved to next generations now. We need to JV AVA6000 to get funds but it can’t be allowed to be a distraction and delay the real money earning life savers.

NASDAQ IPO is a way off yet

If Gemini is like ChatGPT then you can phrase the question in a way that manipulates it into giving you the answer it thinks you want.

I asked it about my time as a TT player which was far from impressive. Then I followed up by asking (what the legal profession would call leading questions). All of a sudden I’d been far more successful!!!

I retired 20 years ago. I can definitely recommend it providing you’ve got a six figure pension.

Yeboha

No. All good. And you must give up your conspiracy theories

Paul

I note you identify three big ‘ifs’ on the road to Avacta’s success. Yes the science has to be great (although many fortunes have been made by selling duff products) but Avacta needs financial backing. I invested in a cracking technical innovation but the big players refused to license it so company capital dwindled until one finally bought the IPR for pennies.

I am not saying that it will happen here but we’ve a long way to go.

. . . and for good measure:

“prodrugs, like AVA6000, offer a targeted approach by activating drugs in the tumor microenvironment, they face some unique challenges that make them less attractive for large-scale investment:

Limited Precision Compared to ADCs: Prodrugs are typically activated by enzymes or conditions present in the tumor microenvironment, but this approach is generally less precise than ADCs, which target specific tumor-associated antigens on cancer cells. This lower specificity can reduce the effectiveness of prodrugs and lead to more systemic toxicity, limiting their appeal.

Narrower Applicability: Prodrugs often rely on specific enzymatic profiles in the tumor, which might not be as widely applicable as antigen targeting in ADCs. For example, a prodrug like AVA6000 depends on fibroblast activation protein (FAP), which is expressed in some, but not all, tumors. This limits the types of cancers that prodrugs can effectively treat, reducing their potential market.

Prodrugs are Not New: The concept of prodrugs has been around for decades, and while some prodrugs have seen success, their overall development trajectory has not been as revolutionary as newer platforms like ADCs or immunotherapies. This leads to less excitement and fewer breakthroughs compared to the innovative potential seen in ADCs.”

Goodnight

Thanks

Mcsquares

You’ll never get another chance to buy at these levels. Fill your boots.

DYOR

Yeboha

Yes I will and gladly.

In fact I have admitted when I’ve been wrong in the past. Apre enjoys regularly reminding me of one such occasion

I agree with you that we should go higher than £2 a lot higher if P2 delivers the results we would expect. But we still need some sort of buy in from BP. If it’s a T/O then there is a risk we get scr*wed. I would prefer some sort of lucrative JV.

However we haven’t got all the time in the world. The very well researched on here may have read all that Avacta have told us many times. Delighting in the nuances and dreaming of great riches. But most of them do little to research the other approaches to cancer treatment. The most obvious being ADCs where at least two drugs have proven efficacy. Why are BP spending so much on ADC development they wail. To quote one recent report:

“The intense investment in ADC development is driven by their high precision, broad applicability, technological complexity, and the potential for significant commercial returns. They represent an evolving, innovative platform with multiple avenues for enhancement and expansion across different cancers. On the other hand, while prodrugs offer targeted treatment, their narrower scope, challenges in achieving precise targeting, and slower innovation have led to relatively lower levels of investment and excitement compared to ADCs.”

Anyone who has successfully invested for a long time knows that just concentrating your research on one share to the exclusion of its competitors can lead to tears.

Just saying. For a friend.

GLA

I remember wishes like this from two years ago. That is all they are, wishful thinking. If some on here are right and there is a T/O this year, then we won’t get £2.

Sadly original post deleted from Twitter.

At least CC could claim she had provided shareholder value = twice the offer price. It would be better if we got shares in the company doing the T/O

IMHO

Bein

But why would they?

If P2 starts showing the results we expect then CC will agree a JV with Novartis for 6000 and maybe 3996. Enough to fund pipeline development and then sky truly is the limit.

. . . . although those are pretty sizeable buys delayed from yesterday 😄😄😄😄😄

Why does the BB continue to be cluttered up with absolute ramping drivel that never comes true.

It works. They are devising a strategy to pick and develop the drugs with the best potential and it’s steady as she goes for at least 6 months. Get over it and wait patiently.

Yep. The science is everything 🚀

Buen

“We can all believe what we want. I believe I'll have another beer”

Apparently not. Some people on here get regularly shouted down when the post what they believe